TAŞKIN, S. Et Al. 2013. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer. ARCHIVES OF GYNECOLOGY AND OBSTETRICS , vol.288, no.6 , 1399-1403.

TAŞKIN, S., GÜNGÖR, M., Ortac, F., & Oztuna, D., (2013). Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer. ARCHIVES OF GYNECOLOGY AND OBSTETRICS , vol.288, no.6, 1399-1403.

TAŞKIN, SALİH Et Al. "Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer," ARCHIVES OF GYNECOLOGY AND OBSTETRICS , vol.288, no.6, 1399-1403, 2013

TAŞKIN, SALİH Et Al. "Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer." ARCHIVES OF GYNECOLOGY AND OBSTETRICS , vol.288, no.6, pp.1399-1403, 2013

TAŞKIN, S. Et Al. (2013) . "Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer." ARCHIVES OF GYNECOLOGY AND OBSTETRICS , vol.288, no.6, pp.1399-1403.

@article{article, author={SALİH TAŞKIN Et Al. }, title={Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer}, journal={ARCHIVES OF GYNECOLOGY AND OBSTETRICS}, year=2013, pages={1399-1403} }